Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00183820 · FLOW

Participant flow

Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    paclitaxel, gemcitabine, and oxaliplatin: 1. Paclitaxel 170 mg/m2 IV d 1 14 days 2. Gemcitabine 800 mg/m2 IV d 1 14 days 3. Oxaliplatin 100 mg/m2 IV d 1 14 days
    id
    FG000
    title
    Paclitaxel, Gemcitabine, and Oxaliplatin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Alternative therapy received
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      non-compliance
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        30
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Recruitment for this study opened in November 2004 and closed in June 2012. All subjects were seen and treated in the medical clinics at the University of Southern California and Los Angeles General Medical Center.
Complete source fields
groups
  1. description
    paclitaxel, gemcitabine, and oxaliplatin: 1. Paclitaxel 170 mg/m2 IV d 1 14 days 2. Gemcitabine 800 mg/m2 IV d 1 14 days 3. Oxaliplatin 100 mg/m2 IV d 1 14 days
    id
    FG000
    title
    Paclitaxel, Gemcitabine, and Oxaliplatin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Alternative therapy received
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      non-compliance
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        30
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        19
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Recruitment for this study opened in November 2004 and closed in June 2012. All subjects were seen and treated in the medical clinics at the University of Southern California and Los Angeles General Medical Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice